In cancer management, the cyclooxygenase (COX)–targeted approach has shown great
promise in anticancer therapeutics. However, the use of COX-2 inhibitors has side effects …

The EP4 prostanoid receptors are one of four receptor subtypes for prostaglandin E2
(PGE2). Therefore, EP4 may play an important role in cancer progression. However, little …

The use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with lower risks for
esophageal, gastric and colon cancers as well as other solid tumors. The antitumor effect of …

We previously established that COX‐2 overexpression promotes breast cancer progression
and metastasis. As long‐term use of COX‐2 inhibitors (COX‐2i) can promote thrombo …

Cyclooxygenase (COX)-generated prostaglandin E 2 (PGE 2) plays critical roles in
colorectal carcinogenesis. Recently, we have shown that PGE 2 and transforming growth …

Abstract Prostaglandin E2 (PGE 2), a major cyclooxygenase (COX) metabolite, plays
important roles in tumor biology. We studied the role of EP2, a receptor for PGE 2, in tumor …

Recent evidence indicates that cyclooxygenase‐2 (COX‐2) and epidermal growth factor
receptor (EGFR) are involved in hepatocarcinogenesis. This study was designed to evaluate …

The cyclooxygenase-2 (COX-2) enzyme is frequently overexpressed in epithelial
malignancies including those of the breast, prostate, lung, kidney, ovary, and liver and …

Prostaglandin E2 (PGE2), a major cyclooxygenase (COX-2) metabolite, plays important
roles in tumor biology and its functions are mediated through one or more of its receptors …

Prostaglandin E2 (PGE2)‐dependent effects on various cell responses are regulated by
respective PGE2 receptors (EP1, EP2, EP3, EP4) expressing in target cells. Alveolar type II …